Therapeutic Potential of Luteolin for Diabetes Mellitus and Its Complications

Overview

Journal Chin J Integr Med

Date 2024 Sep 20

PMID 39302570

Authors

Xiao-Qin Chang

Ren-Song Yue

Affiliations

Soon will be listed here.

Abstract

The global prevalence of diabetes mellitus (DM) and its complications has been showing an upward trend in the past few decades, posing an increased economic burden to society and a serious threat to human life and health. Therefore, it is urgent to investigate the effectiveness of complementary and alternative therapies for DM and its complications. Luteolin is a kind of polyphenol flavonoid with widely existence in some natural resources, as a safe dietary supplement, it has been widely studied and reported in the treatment of DM and its complications. This review demonstrates the therapeutic potential of luteolin in DM and its complications, and elucidates the action mode of luteolin at the molecular level. It is characterized by anti-inflammatory, antioxidant, and neuroprotective effects. In detail, luteolin can not only improve endothelial function, insulin resistance and β-cell dysfunction, but also inhibit the activities of dipeptidyl peptidase-4 and α-glucosidase. However, due to the low water solubility and oral bioavailability of luteolin, its application in the medical field is limited. Therefore, great importance should be attached to the joint application of luteolin with current advanced science and technology. And more high-quality human clinical studies are needed to clarify the effects of luteolin on DM patients.

Citing Articles

Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies.

Mahwish , Imran M, Naeem H, Hussain M, Alsagaby S, Al Abdulmonem W Food Sci Nutr. 2025; 13(1):e4682.

PMID: 39830909 PMC: 11742186. DOI: 10.1002/fsn3.4682.

References

Demir S, Nawroth P, Herzig S, Ekim Ustunel B . Emerging Targets in Type 2 Diabetes and Diabetic Complications. Adv Sci (Weinh). 2021; 8(18):e2100275. PMC: 8456215. DOI: 10.1002/advs.202100275. View

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

Chen H, Liu C, Cheng C, Zheng L, Huang K . Effects of Apelin Peptides on Diabetic Complications. Curr Protein Pept Sci. 2017; 19(2):179-189. DOI: 10.2174/1389203718666170918154728. View

Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-281. DOI: 10.1016/j.diabres.2018.02.023. View

Kaur P, Mittal A, Nayak S, Vyas M, Mishra V, Khatik G . Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus. Curr Drug Targets. 2018; 19(15):1738-1766. DOI: 10.2174/1389450119666180727142902. View

Gan Q, Wang J, Hu J, Lou G, Xiong H, Peng C . The role of diosgenin in diabetes and diabetic complications. J Steroid Biochem Mol Biol. 2020; 198:105575. DOI: 10.1016/j.jsbmb.2019.105575. View

Chu C, Li D, Zhang S, Ikejima T, Jia Y, Wang D . Role of silibinin in the management of diabetes mellitus and its complications. Arch Pharm Res. 2018; 41(8):785-796. DOI: 10.1007/s12272-018-1047-x. View

Rahman M, Rahaman M, Islam M, Rahman F, Mannan Mithi F, Alqahtani T . Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects. Molecules. 2022; 27(1). PMC: 8746501. DOI: 10.3390/molecules27010233. View

Lopez-Lazaro M . Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009; 9(1):31-59. DOI: 10.2174/138955709787001712. View

10.

Choi B, Lim D, Lee J, Gao S, Kwon D, Kim B . Luteolin suppresses cisplatin-induced apoptosis in auditory cells: possible mediation through induction of heme oxygenase-1 expression. J Med Food. 2008; 11(2):230-6. DOI: 10.1089/jmf.2007.591. View

11.

El-Bassossy H, Abo-Warda S, Fahmy A . Chrysin and luteolin attenuate diabetes-induced impairment in endothelial-dependent relaxation: effect on lipid profile, AGEs and NO generation. Phytother Res. 2013; 27(11):1678-84. DOI: 10.1002/ptr.4917. View

12.

Kim J, Kwon C, Son K . Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. Biosci Biotechnol Biochem. 2001; 64(11):2458-61. DOI: 10.1271/bbb.64.2458. View

13.

Fan J, Johnson M, Lila M, Yousef G, Gonzalez de Mejia E . Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management. Evid Based Complement Alternat Med. 2013; 2013:479505. PMC: 3773436. DOI: 10.1155/2013/479505. View

14.

Alshehri S, Imam S, Altamimi M, Hussain A, Shakeel F, Elzayat E . Enhanced Dissolution of Luteolin by Solid Dispersion Prepared by Different Methods: Physicochemical Characterization and Antioxidant Activity. ACS Omega. 2020; 5(12):6461-6471. PMC: 7114142. DOI: 10.1021/acsomega.9b04075. View

15.

Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, Hashimoto T . Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-κB inactivation in macrophages co-cultured with intestinal epithelial cells. Biofactors. 2013; 39(5):522-33. DOI: 10.1002/biof.1091. View

16.

Aziz N, Kim M, Cho J . Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018; 225:342-358. DOI: 10.1016/j.jep.2018.05.019. View

17.

Wang Z, Zeng M, Wang Z, Qin F, Chen J, He Z . Dietary Luteolin: A Narrative Review Focusing on Its Pharmacokinetic Properties and Effects on Glycolipid Metabolism. J Agric Food Chem. 2021; 69(5):1441-1454. DOI: 10.1021/acs.jafc.0c08085. View

18.

Zhang W, Li D, Shan Y, Tao Y, Chen Q, Hu T . Luteolin intake is negatively associated with all-cause and cardiac mortality among patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2023; 15(1):59. PMC: 10039598. DOI: 10.1186/s13098-023-01026-9. View

19.

Muruganathan N, Dhanapal A, Baskar V, Muthuramalingam P, Selvaraj D, Aara H . Recent Updates on Source, Biosynthesis, and Therapeutic Potential of Natural Flavonoid Luteolin: A Review. Metabolites. 2022; 12(11). PMC: 9696498. DOI: 10.3390/metabo12111145. View

20.

Choi J, Islam M, Ali M, Kim Y, Park H, Sohn H . The effects of C-glycosylation of luteolin on its antioxidant, anti-Alzheimer's disease, anti-diabetic, and anti-inflammatory activities. Arch Pharm Res. 2014; 37(10):1354-63. DOI: 10.1007/s12272-014-0351-3. View